All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Elevated plasma fibrin d-dimer (DD) levels suggest the presence of hypercoagulability or prothrombotic state \[[@pone.0172272.ref001]\]. Thus DD has been taken as a potential non-invasive marker of thrombogenesis and thromboembolism. In clinical settings such as deep venous thrombosis (DVT) \[[@pone.0172272.ref002]\], pulmonary embolism (PE) \[[@pone.0172272.ref003],[@pone.0172272.ref004]\] and acute aortic dissection \[[@pone.0172272.ref005],[@pone.0172272.ref006]\], DD has an excellent negative predictive value. Pooled data of 10 studies showed that an elevated DD was independently associated with twice as much increased risk of near-term systemic embolism \[[@pone.0172272.ref007]\].

Left atrial spontaneous echo contrast (SEC) and left atrial thrombus (LAT), which are identified by trans-esophageal echocardiography (TEE), have been confirmed to be associated with increased thromboembolic risk \[[@pone.0172272.ref008],[@pone.0172272.ref009],[@pone.0172272.ref010]\]. As a semi-invasive procedure, however, TEE can induce obvious discomfort and has potential risk of esophageal damage \[[@pone.0172272.ref011]\]. Thus, it is hard to apply TEE to all patients with left atrial dysfunction, such as those with atrial fibrillation, atrial flutter and mitral stenosis. Some studies suggested that DD is a valuable parameter to exclude left atrial SEC and LAT \[[@pone.0172272.ref012],[@pone.0172272.ref013]\]. However, these studies included a relative small number of patients with inconsistent outcomes. Therefore, we performed a systemic review and meta-analysis to evaluate the association between DD and the presence of LAT/SEC.

Materials and methods {#sec006}
=====================

Search strategy {#sec007}
---------------

We searched the MEDLINE and EMBASE databases for articles published from initiations to Feb. 2016, and identified additional studies by hand-searching references of original articles or review articles on this topic and by personal contact with investigators. The search terms and algorithm for the literature search were as follows: ("fibrin fragment D" \[MeSH\] OR "d-dimer" OR "d-dimer fibrin" OR "d-dimer fragments" OR "fibrin fragment D1 dimer" OR "fibrin fragment DD" OR "fibin fragment D-dimer") AND(("atrial function, left"\[MeSH\] AND ("thromboses" OR "thrombus"\[MeSH\]) OR "left atrial thrombus" OR "appendage thrombus" OR "spontaneous echo contrast"). The search language was restricted to English.

Selection of studies {#sec008}
--------------------

The selection of eligible studies was performed by two independent reviewers (H.W. and S.W.). Inconsistency regarding the selection of studies was resolved by consensus with the senior consultants (Y.Y. and J.Z.). Studies were selected if they met the following criteria: 1) DD was a study factor; 2) the outcome of interest was any type of TEE-identified left atrial SEC or LAT; 3) studies had sufficient data for pooling, i.e., number of subjects, mean and standard deviation (or median and range) of DD between SEC/LAT group and control group for continuous data; or frequencies and cutoff values of DD to predict the presence of LAT for categorical data; 4) studies were not duplicates. Review articles, case-reports and studies with insufficient data for pooling were excluded in case of no response after contacting the authors twice. Left atrial SEC was defined as dynamic smoke-like echoes with characteristic swirling patterns in left atrium or its appendage. LAT was defined as echo-dense intracavitary mass adjacent to the endocardial surface of the left atrium or its appendage and acoustic characteristics that clearly differentiated from such normal structures as endocardium or pectinate muscles.

Data extraction {#sec009}
---------------

Baseline characteristics of included studies (i.e., study settings, period of publishing, country, mean age, percentage of males, history of atrial fibrillation (AF), mitral stenosis, acute ischemic stroke and anticoagulation, instruments for TEE, methods used for measuring DD, excluded population), data of outcomes, i.e., mean DD and standard deviation in two groups, the log ratio of the risk of LAT among individuals in the top third vs those in the bottom third based on the measurement of DD, and the cutoff value of DD selected for maximal sensitivity and the frequency of presenting LAT, were extracted by 2 independent reviewers (H.W. and S.W.) using a standardized data extraction form. Disagreement was resolved by consensus with the senior consultants (Y.Y. and J.Z.). Missing data was obtained by contacting the corresponding authors.

Risk of bias assessment {#sec010}
-----------------------

Two authors (A.Z. and L.Y.) independently assessed risk of bias of each study. For studies reporting mean DD difference, the quality assessment was conducted via the Newcastle and Ottawa risk of bias criteria \[[@pone.0172272.ref014]\] for assessing the quality of case-control studies. Three domains were considered, i.e., selection of study groups (4 items), comparability of groups (2 items), and ascertainment of exposure (2 items). Each item was graded either 0 or 1 with a total score ranging from 0 to 8; higher total score reflected higher quality and lower risk of bias. For the quality assessment of studies' diagnostic accuracy of DD on the prediction of LAT, the bias was assessed via QUADAS-2\[[@pone.0172272.ref015]\], including four domains in risk of bias, i.e., patient selection, index test, reference standard, and flow and timing, and three domains in applicability, i.e. patient selection, index test and reference standard. Studies were judged as "low", "high" or "unclear" according to domains relating to risk of bias or applicability. Disagreement was resolved by consensus after discussion with senior consultants (Y.Y. and J.Z).

Statistical analysis {#sec011}
--------------------

For continuous outcomes, the mean DD difference between SEC/LAT and control group was estimated for each study and pooled using a standardized mean difference (SMD). If data of DD was reported in the form of median, range and size only, the mean and the variance were converted according to the method reported by Hozo et al.\[[@pone.0172272.ref016]\] The ratios of risk for the presence of LAT based on the tertiles of DD levels were estimated by the method reported by Danesh J. et al\[[@pone.0172272.ref017]\]. For dichotomous outcomes, the true positive, true negative, false positive and false negative of a DD cutoff value on the presence of LAT were estimated for each study. Bivariate meta-analysis was applied for pooling diagnostic parameters including sensitivity, specificity, and likelihood ratio positive of DD level on LAT using midas command in STATA.

Heterogeneity of the effect estimates was assessed and quantified using the Q statistic and I^2^ statistic. If significant heterogeneity was detected (P value \<0.10 or I^2^≥25%), a random-effect model (Dersimonian & Laird method) was applied; otherwise, a fixed-effect model (inverse-variance method) was used. Sources of heterogeneity were explored by fitting each of the co-variables (i.e. mean age, study settings, sample size, percentage of males, mitral stenosis (Yes/No), AF (percentage), acute ischemic stroke (Yes/No) and anticoagulation (Yes/No), cuffoff value of DD) in meta-regression models. Publication bias was assessed using an Egger's test and funnel plot. All analyses were performed using STATA software (version 12.0, StataCorp, USA). A two-sided test with P-value \<0.05 was considered statistically significant except for the test of heterogeneity, in which a P-value \<0.10 was used.

Results {#sec012}
=======

The flow diagram of detailed search was illustrated in [Fig 1](#pone.0172272.g001){ref-type="fig"}. A total of 71 publications were identified by searching the MEDLINE (28 publications) and EMBASE (43 publications) databases. Of these 71 records, 25 duplications, 1 review and 10 case reports were excluded, leaving 35 records for further assessment. After excluding 14 records due to a lack of either outcome of interests (7 records) or data for pooling (7 records), 21 studies fulfilled selection criteria and were finally included in this systemic review. Details of reasons for exclusion of the studies are also presented in [Fig 1](#pone.0172272.g001){ref-type="fig"}.

![Flow diagram illustrating the systemic literature and study selection process.](pone.0172272.g001){#pone.0172272.g001}

Characteristics of included studies are presented in [Table 1](#pone.0172272.t001){ref-type="table"}. All of the studies were observational studies, among which 8 studies \[[@pone.0172272.ref012],[@pone.0172272.ref013],[@pone.0172272.ref018],[@pone.0172272.ref019],[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref022],[@pone.0172272.ref023]\] were prospective design. Mean age of study participants ranged from 29.7 to 76.0 years, and the percentage of males ranged from 28.4% to 77.8%. Twelve (57.1%) studies confined the population to patients with AF \[[@pone.0172272.ref013],[@pone.0172272.ref019],[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref024],[@pone.0172272.ref025],[@pone.0172272.ref026],[@pone.0172272.ref027],[@pone.0172272.ref028],[@pone.0172272.ref029],[@pone.0172272.ref030],[@pone.0172272.ref031]\], with reported percentages of patients with AF ranged from 20%-86% in 7 (33.3%) studies \[[@pone.0172272.ref012],[@pone.0172272.ref018],[@pone.0172272.ref022],[@pone.0172272.ref032],[@pone.0172272.ref033],[@pone.0172272.ref034],[@pone.0172272.ref035]\], besides, 2 (9.5%) studies focused on patients in sinus rhythm \[[@pone.0172272.ref023],[@pone.0172272.ref036]\], 4 studies (19.0%) restricted to the population of patients with mitral stenosis \[[@pone.0172272.ref023],[@pone.0172272.ref033],[@pone.0172272.ref035],[@pone.0172272.ref036]\], among which, 2 studies reported the prevalence of mitral stenosis ranged from 6.0% to 27.5% \[[@pone.0172272.ref028],[@pone.0172272.ref037]\]. Of 21 included studies, 12 (57.1%) studies reported mean or median DD values \[[@pone.0172272.ref013],[@pone.0172272.ref018],[@pone.0172272.ref019],[@pone.0172272.ref024],[@pone.0172272.ref025],[@pone.0172272.ref026],[@pone.0172272.ref027],[@pone.0172272.ref029],[@pone.0172272.ref030],[@pone.0172272.ref032],[@pone.0172272.ref035],[@pone.0172272.ref037]\], 5 (23.8%) studies reported frequency and DD cutoff value on LAT \[[@pone.0172272.ref022],[@pone.0172272.ref023],[@pone.0172272.ref031],[@pone.0172272.ref033],[@pone.0172272.ref034]\], and 4 (19.0%) studies reported both \[[@pone.0172272.ref012],[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref036]\]. 11 studies have available information to calculate a ratio of the presence of LAT among individuals in the top vs bottom third of DD levels\[[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref022],[@pone.0172272.ref023],[@pone.0172272.ref024],[@pone.0172272.ref028],[@pone.0172272.ref029],[@pone.0172272.ref031],[@pone.0172272.ref033],[@pone.0172272.ref034],[@pone.0172272.ref036]\].

10.1371/journal.pone.0172272.t001

###### Characteristics of eligible studies.

![](pone.0172272.t001){#pone.0172272.t001g}

  Author(ref.)                                       Year published   Country     Data collection                  Sample size   Observational group (n)   Age (years)   Males (%)   AF (%)   MS      Acute stroke   Anticoagulation   Instruments for TEE                                                     Methods for DD measurement    Cutoff of DD (ug/ml)   Excluded population
  -------------------------------------------------- ---------------- ----------- -------------------------------- ------------- ------------------------- ------------- ----------- -------- ------- -------------- ----------------- ----------------------------------------------------------------------- ----------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Black IW, et al.\[[@pone.0172272.ref013]\]         1993             Australia   Prospective, consecutive         40            SEC/LAT (21)              66            68.9        100      No      No             No                HP21362/3A.Transducer 5 MHz.                                            EIA(dimertest)                UA                     MS, moderate/severe MR or a mitral valve prosthetic.
  Yamamura O, et al.\[[@pone.0172272.ref026]\]       2001             Japan       Retrospective, non-consecutive   19            SEC/LAT (9)               70.8          52.6        100      No      No             No                ATL HDI3000, Philips. Transducer 5 MHz.                                 LPIA(Datron)                  UA                     Severe infection, hepatic/renal dysfunction, anticoagulation.
  Turchetti V, et al.\[[@pone.0172272.ref032]\]      2001             Italy       Retrospective, non-consecutive   45            SEC/LAT (20)              72.2          77.8        80       No      No             No                Undefined.                                                              Immunofiltration (NycoCard)   UA                     Severe hypertension, lipoidoproteinosis, CRF, DM, severe cerebrovasculopathy, anticoagulation, major valvular disease.
  Sato M, et al.\[[@pone.0172272.ref018]\]           2006             Japan       Prospective, consecutive         43            SEC/LAT (18)              70.8          57.4        22       No      Yes            No                ATL HDI-5000, Philips. Transducer 4--7 MHz.                             LPIA(Diayatoron)              UA                     PE, infection and DVT.
  Topaloglu, S., et al.\[[@pone.0172272.ref035]\]    2007             Turkey      Retrospective, non-consecutive   46            SEC/LAT (24)              34.0          17.4        39.1     Yes     No             No                Toshiba Ref510 PB, Transducer 5 MHz.                                    LPIA                          UA                     Renal/hepatic insufficiency, systemic embolism, LAT, active rheumatism, CHD,DM,DVT, severe MR, malignancy, and hypertension.
  Cianfrocca C, et al.\[[@pone.0172272.ref019]\]     2010             Italy       Prospective, consecutive         159           SEC/LAT (52)              67.0          47.2        100      No      No             No                Vivid 7, GE. Transducer 2.5--3.5--4.0 MHz.                              Undefined                     UA                     Infection, neoplastic, AMI/stroke ≤ 3m, thyrotoxicosis, steroids, NSAIDs, HRT, hematologic, renal/hepatic dysfunction; previous cardioversion.
  Jin YY, et al.\[[@pone.0172272.ref025]\]           2011             China       Retrospective, consecutive       154           SEC/LAT(46)               59.4          59.1        100      No      No             No                Sonos4500/5000, Philips, or Acuson C256, GE. Transducer 2.5--5.0 MHz.   LPIA(Sysmex CA7000)           UA                     VHD, AID, infection, active rheumatism, renal/hepatic impairment, malignant, ACS.
  Abu-Mahfouz M, et al. \[[@pone.0172272.ref012]\]   2012             USA         Prospective, consecutive         124           SEC/LAT(21)               55.4          63.7        76       No      No             No                Sonos 5500, Philips. Transducer: undefined.                             ELISA(Stago)                  0.500                  Infection, bleeding, blood transfusion ≤ 1m, surgery, ACS or DVT or PE ≤ 3m, thrombolysis, anticoagulation\>7d, malignancy, AID.
  Numa S, et al.\[[@pone.0172272.ref024]\]           2014             Japan       Retrospective, consecutive       468           SEC/LAT(234)              67.0          71.3        100      No      No             No                SSH770A, Toshiba or Vivid E9, GE. Transducer 5 MHz.                     Undefined                     UA                     Acute CVD, infection, taking antihyperuricemic drugs.
  Sakai, M., et al.\[[@pone.0172272.ref037]\]        1994             Japan       Retrospective, non-consecutive   34            LAT(14)                   76.0          32.5        100      27.5%   12.5%          No                SA270A, Toshiba. Transducer 5 MHz.                                      LPIA (Diamondtron)            UA                     Anticoagulation, DIC, hepatic disease.
  Heppell RM, et al.\[[@pone.0172272.ref029]\]       1997             UK          Retrospective, consecutive       107           LAT(19)                   69.4          64.5        100      No      No             No                Toshiba or Vingmed. Transducer 5--6 MHz.                                ELISA (Stago)                 UA                     RHD, prosthetic heart valve, anticoagulation, haemostatic impairment.
  Nakajima K.\[[@pone.0172272.ref027]\]              2000             Japan       Retrospective, non-consecutive   122           LAT(28)                   73.0          62.3        100      No      No             No                HP Sonos500-21363. Transducer: undefined.                               Undefined                     UA                     RHD.
  Igarashi Y.\[[@pone.0172272.ref028]\]              2000             Japan       Retrospective, consecutive       91            LAT(19)                   67.0          62.0        100      6%      No             No                SSA270A, Toshiba, Transducer 5.0-MHz.                                   Undefined                     UA                     Undefined.
  Somloi M, et al.\[[@pone.0172272.ref022]\]         2003             Hungary     Prospective, consecutive         73            LAT(9)                    69.0          52.0        86       No      5%             No                ATL HDI3500, Philips. Transducer: 4--7 MHz.                             Roche                         0.600                  Thromboembolism ≤ 2 m, anticoagulation ≥7 d, equivocal TEE results.
  Habara S, et al.\[[@pone.0172272.ref020]\]         2007             Japan       Prospective, consecutive         925           LAT(83)                   68.8          67.4        100      No      No             No                Sonos 2500/5500, Philips. Transducer 2.5--5 MHz.                        LPIA (Mitsubishi)             1.150                  VHD, prosthetic valve replacement, aortic aneurysm, LVT, AD, DVT and PE.
  Sugiura S, et al.\[[@pone.0172272.ref021]\]        2012             Japan       Prospective, consecutive         225           LAT(23)                   62.0          77.8        100      No      No             Yes               Vivid 7, GE. transducer 4--10 MHz.                                      LPIA (Mitsubishi)             0.125                  VHD.
  Naresh K, et al.\[[@pone.0172272.ref036]\]         2014             India       Retrospective, non-consecutive   59            LAT(7)                    UA            UA          0        Yes     No             No                Undefined.                                                              Roche                         0.400                  Undefined.
  Rajappa M, et al.\[[@pone.0172272.ref033]\]        2013             India       Retrospective, non-consecutive   46            LAT(24)                   29.7          32.6        83       Yes     No             UA                Undefined.                                                              ELISA kits                    4.000                  Inadequate TEE results, renal/hepatic dysfunction, infection, neoplastic disease, stroke or PVD.
  Kadle N, et al.\[[@pone.0172272.ref034]\]          2013             USA         Retrospective, non-consecutive   49            LAT(6)                    63.0          56.0        52       UA      48%            UA                Undefined.                                                              LPIA                          0.200                  Undefined.
  Yoshida, N., et al.\[[@pone.0172272.ref031]\]      2015             Japan       Retrospective, consecutive       58            LAT(4)                    67.0          56.9        100      No      No             Yes               Vivid 7,GE or iE33,Philips. Transducer: undefined.                      LPIA                          1.00                   Severe MR, MS, and DCM.
  Kurakula N,et al.\[[@pone.0172272.ref023]\]        2016             India       Prospective, consecutive         108           LAT(12)                   35.6          28.4        0        Yes     No             No                iE33,Philips. Tranducer: undefined.                                     Roche                         0.510                  Moderate/severe MR, AS or AR, AF, renal/hepatic dysfunction, hypertension, DM, CAD, active RHD, infection, malignancy, surgery or trauma, pregnancy, antiplatelet, anticoagulation.

Characteristics of eligible studies.

AF, atrial fibrillation; MS, mitral stenosis; TEE, trans-esophageal echocardiography; DD, d-dimer; SEC, spontaneous echo contrast; LAT, left atrial thrombus; UA, unavailable; MR, mitral regurgitation; CRF, chronic renal failure; DM, diabetes mellitus; PE, pulmonary embolism; DVT, deep venous thrombosis; AMI, acute myocardial infarction; NSAID, non-steroid anti-inflammation drug; HRT, hormone replacement therapy; VHD, valvular heart disease; AID, autoimmune disease; CHD, chronic heart disease; ACS, acute coronary syndrome; CVD, cerebrovascular disease; DIC, disseminated intravascular coagulation; RHD, rheumatic heart disease; LVT, left ventricular thrombosis; AD, aortic dissection; PVD,; AS, aortic stenosis; AR, aortic regurgitation; CAD, coronary artery disease; DCM, dilated cardiomyopathy.

Risk of bias assessment {#sec013}
-----------------------

The risks of bias of 16 studies used for pooling SMD of DD levels were assessed via the Newcastle and Ottawa risk of bias criteria \[[@pone.0172272.ref014]\], in which total scores ranged from 5 to7 with a median of 6 for six prospective studies, and from 4 to 6 with a median of 5 for ten retrospective studies. Four and nine studies had scores equal or higher than median for prospective and retrospective designs, respectively (see [Fig 2](#pone.0172272.g002){ref-type="fig"}). [Fig 3](#pone.0172272.g003){ref-type="fig"} presents the risk of bias and concerns regarding applicability of 9 eligible diagnostic test studies via QUADAS-2. In general, three domains for concerns regarding applicability were estimated as "low" risk if the patients included, index test and reference standard used were well matched to the review question. Three studies which were not consecutively or randomly enrolled \[[@pone.0172272.ref033],[@pone.0172272.ref034],[@pone.0172272.ref036]\] and six studies without pre-specified the threshold of index test \[[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref022],[@pone.0172272.ref034],[@pone.0172272.ref036]\] were evaluated as"high"risk of bias in patient selection and index test domain respectively. The reference standard domain of two studies was classified to "unknown" because the authors did not report whether the clinicians were blinded to the index test results when they established the diagnosis \[[@pone.0172272.ref033],[@pone.0172272.ref034]\]. Therefore, neither partial nor differential verification bias could be completely excluded.

![Quality assessment of 16 observational studies by the Newcastle and Ottawa risk of bias criteria.](pone.0172272.g002){#pone.0172272.g002}

![Risk of bias assessment of 9 diagnostic tests by QUADAS-2.](pone.0172272.g003){#pone.0172272.g003}

Pooled mean d-dimer differences {#sec014}
-------------------------------

Nine studies \[[@pone.0172272.ref012],[@pone.0172272.ref013],[@pone.0172272.ref018],[@pone.0172272.ref019],[@pone.0172272.ref024],[@pone.0172272.ref025],[@pone.0172272.ref026],[@pone.0172272.ref032],[@pone.0172272.ref035]\] reported mean DD differences between patients with (n = 445) and without SEC/LAT (n = 644), and seven studies reported the differences between patients with (n = 193) and without LAT (n = 1370), see [Fig 4](#pone.0172272.g004){ref-type="fig"}. Data was combined and the estimated total SMD was 1.29 \[95% CI: 0.51, 2.08\]. This indicated that mean DD in patients with SEC and/ or LAT was 2.29 times higher than mean DD of controls.

![Forest plot of the standard mean difference in d-dimer levels between patients with and without left atrial spontaneous echo contrast/left atrial thrombus.](pone.0172272.g004){#pone.0172272.g004}

Considerable heterogeneity (Chi-square = 765.91, P-value \<0.001, I^2^ = 98%) was also observed in the qualitative synthesis. In SEC/LAT subgroup, the estimated SMD was 0.42 \[95% CI: 0.08, 0.77\], indicating that a slightly elevated DD level existed in patients with SEC/LAT, and the total SMD majorly originated from the LAT subgroup, in which the estimated SMD was 2.34 \[95% CI: 1.01, 3.68\].

Besides, a high considerable heterogeneity was also presented in both subgroups (in SEC/LAT subgroup: Chi-square = 43.24, P \<0.001, I^2^ = 81.5%; LAT subgroup, Chi-square = 288.35, P \<0.001, I^2^ = 97.0%), and thus meta-regression was conducted to explore the possible sources of heterogeneity. Except that sample size was found to be a source of heterogeneity (coefficient = -0.0036, P = 0.033), no significant difference was observed in the coefficient of subgroup (SEC/LAT or LAT), mean age, percentage of males, history of AF, acute ischemic stroke or anticoagulation therapy with the adjusted I^2^ of 84.78%. Funnel plot and Egger's test revealed no evidence of publication bias (coefficient = 3.3881, P = 0.408). (see [Fig 5](#pone.0172272.g005){ref-type="fig"})

![Egger's test for the assessment of publication bias of 16 observational studies.\
SND, standard normal deviate.](pone.0172272.g005){#pone.0172272.g005}

Association between d-dimer and the presence of LAT {#sec015}
---------------------------------------------------

Eleven studies \[[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref022],[@pone.0172272.ref023],[@pone.0172272.ref024],[@pone.0172272.ref028],[@pone.0172272.ref029],[@pone.0172272.ref031],[@pone.0172272.ref033],[@pone.0172272.ref034],[@pone.0172272.ref036]\] were included for estimating the association of DD on the presence of LAT. Of 1856 involved patients (weighted mean age of 60.3 years old), 238 patients have TEE identified LAT. Only 4 studies \[[@pone.0172272.ref020],[@pone.0172272.ref021],[@pone.0172272.ref023],[@pone.0172272.ref024]\] made adjustments for potential confounders. The comparison of individuals with DD levels in the top third vs those in the bottom third yielded a combined risk ratio for the presence of LAT of 3.84 \[95% CI: 2.35--6.28\] (see [Fig 6](#pone.0172272.g006){ref-type="fig"}.), and the estimated mean in these two groups were 1.10 and 0.32 ug/ml. There was no significant heterogeneity among the publish findings of the 11 studies (Q test = 18.45, P = 0.05, I^2^ = 46%). No significant publication bias was exhibited in Egger's test (coefficient = 0.371, P = 0.741) (see [Fig 7](#pone.0172272.g007){ref-type="fig"}.).

![Risk ratios for the presence of LAT comparing the top third with the bottom third based on d-dimer distributions.](pone.0172272.g006){#pone.0172272.g006}

![Egger's test for the assessment of publication bias of 11 studies.\
SND, standard normal deviate.](pone.0172272.g007){#pone.0172272.g007}

Diagnostic accuracy of d-dimer for the presence of LAT {#sec016}
------------------------------------------------------

Among the nine studies estimating the diagnostic accuracy of DD for the presence of LAT, five studies were prospective designs. Of 1667 included patients, 189 were diagnosed with LAT. The reported DD cutoff values selected for maximal sensitivity varied across studies, ranging from 0.125 to 4.0 ug/ml. The pooled sensitivity, specificity and positive likelihood ratio were 0.75 \[95% CI: 0.65, 0.83\], 0.81 \[95% CI: 0.59, 0.93\] and 4.0 \[95% CI: 1.7, 9.9\], respectively (see SROC in [Fig 8](#pone.0172272.g008){ref-type="fig"}).

![Summary receiver operating characteristic curves (SROC) for overall diagnostic accuracy of d-dimer for the presence of left atrial thrombus.\
① Abu-Mahfouz M et al. \[[@pone.0172272.ref012]\]; ② Habara S et al. \[[@pone.0172272.ref020]\]; ③ Sugiura S et al. \[[@pone.0172272.ref021]\]; ④ Rajappa M et al. \[[@pone.0172272.ref033]\];⑤ Somloi M et al. \[[@pone.0172272.ref022]\]; ⑥ Kadle N et al. \[[@pone.0172272.ref034]\]; ⑦ Naresh K et al. \[[@pone.0172272.ref036]\]; ⑧ Yoshida N et al. \[[@pone.0172272.ref031]\]; ⑨ Kurakula N et al. \[[@pone.0172272.ref023]\].](pone.0172272.g008){#pone.0172272.g008}

This pooled result also had a high heterogeneity (Q test = 23.051, P \< 0.001, I^2^ = 91%). Meta-regression analysis utilizing a joint model exhibited that DD cutoff values, mean age and percentage of males were the main sources of heterogeneity (Chi-square = 7.42, 14.03, 13.69, respectively; all P ≤ 0.02,). A funnel plot showed symmetry of DD effects without significant publication bias (coefficient = 8.721968, P = 0.309). (see [Fig 9](#pone.0172272.g009){ref-type="fig"})

![Funnel plot for the assessment of publication bias of 9 diagnostic tests.\
① Abu-Mahfouz M et al. \[[@pone.0172272.ref012]\]; ② Habara S et al. \[[@pone.0172272.ref020]\]; ③ Sugiura S et al. \[[@pone.0172272.ref021]\]; ④ Rajappa M et al. \[[@pone.0172272.ref033]\];⑤ Somloi M et al. \[[@pone.0172272.ref022]\]; ⑥ Kadle N et al. \[[@pone.0172272.ref034]\]; ⑦ Naresh K et al. \[[@pone.0172272.ref036]\]; ⑧ Yoshida N et al. \[[@pone.0172272.ref031]\]; ⑨ Kurakula N et al. \[[@pone.0172272.ref023]\].](pone.0172272.g009){#pone.0172272.g009}

Discussion {#sec017}
==========

The present systematic review and meta-analysis investigated the mean DD difference between patients with and without TEE-identified left atrial SEC and/or LAT, and estimated the association between DD levels an the presence of LAT. We found that DD significantly elevated in patients with SEC/LAT, particularly among patients with LAT, and had moderate sensitivity and specificity in identifying the presence of LAT.

Our systemic review majorly included the population of AF and mitral stenosis, which have common pathophysiological characteristics of left atrial dilation and blood stasis, and thus cast high risk of LAT, ischemic stroke and systemic embolism \[[@pone.0172272.ref009],[@pone.0172272.ref010],[@pone.0172272.ref019],[@pone.0172272.ref029]\]. Left atrial SEC and LAT are TEE-detected risk markers for thromboembolism \[[@pone.0172272.ref008],[@pone.0172272.ref009],[@pone.0172272.ref010],[@pone.0172272.ref013]\]. Among patients with nonvalvular AF, LAT was observed in 8.8% of patients with sub-therapeutic anticoagulation and 3.6% of patients with sufficient anticoagulation, which was an independent risk factor associated with worse cardiovascular outcomes \[[@pone.0172272.ref038]\]. Despite adequate oral anticoagulation, patients with AF and dense left atrial SEC still suffer from a substantial likelihood of ischemic stroke and death \[[@pone.0172272.ref039]\]. Although a high prevalence of left atrial SEC has been found in patients with LAT \[[@pone.0172272.ref010]\], we identified that DD levels in patients with LAT were substantially higher than those with SEC. Several mechanisms were involved in the pathological conditions of left atrial SEC, including blood stasis and erythrocyte aggregation, which increases blood viscosity, leading to a propensity of thrombosis \[[@pone.0172272.ref013]\]. However, previous study had demonstrated that SEC was not an indicator of platelet activation or fibrin formation \[[@pone.0172272.ref013]\]. In addition, the determination of left atrial SEC in different studies might be hard to harmonize, which depended more on the experience of diagnosticians than LAT. Among consecutive patients with AF, although Numa S., et al.\[[@pone.0172272.ref024]\] and Habara S., et al.\[[@pone.0172272.ref020]\] reported a similar prevalence of LAT (8.5% and 8.9%, respectively), the prevalence of left atrial SEC was significantly varied (49.8% and 14.3%, respectively). These reasons could potentially explain the significant heterogeneity of DD levels among the individuals with left atrial SEC in the subgroup analysis.

The elevated DD level, likewise, was related to the risk of stroke and death, and adds to the predictive value of clinical adverse events in anticoagulated patients with AF \[[@pone.0172272.ref040]\]. Previous meta-analysis indicated that a positive DD test was associated with an increasing risk of stroke and systemic embolism \[[@pone.0172272.ref007],[@pone.0172272.ref041]\], reversely, a negative DD test result was valuable for excluding thrombosis and thromboembolism in patients with DVT and PE \[[@pone.0172272.ref042],[@pone.0172272.ref043]\]. Moreover, high graded left atrial SEC was related to increased DD levels in patients with nonvalvular AF \[[@pone.0172272.ref020]\]. Similar to these studies, our meta-analysis also exhibited considerable association between elevated DD levels and SEC/LAT, particularly among patients with LAT. The ratio risk of the presence of LAT among individuals with DD levels in the top third was about 4 times higher than those in the bottom third.

DD may be a potential valuable marker for diagnosing LAT. In our study, the pooled specificity of DD test was 0.81 \[95% CI: 0.59, 0.93\], indicating that a normal DD level has moderate to high potential to rule out LAT. Therefore, a negative DD value may be helpful to identify low-risk patients for the presence of LAT or thromboembolism, and to reduce unnecessary image screening for them. In addition, a positive DD value also exhibited moderate sensitivity in the prediction of LAT (0.75 \[95% CI: 0.65, 0.83\]), which suggested a potential diagnostic applicability of DD. Therefore, a positive DD value may be a complement to CHA2DS2-VASc score \[[@pone.0172272.ref044]\], and contribute to identify high-risk patients with SEC/LAT for anticoagulation therapy. It is noted that all of the included studies have ruled out other conditions associated with fibrin formation and degradation, such as infection, inflammation, malignancy and thrombus other than left atrium, etc.(see [Table 1](#pone.0172272.t001){ref-type="table"}) Thus, one should be cautious to extensively apply the results to other population or situations.

There are several strengths in our present study. To our knowledge, this is the first systemic review and meta-analysis to evaluate the relationship between DD levels and the presence of left atrial SEC/LAT. A comprehensive search of literatures from 2 main databases were approached, and two reviewers independently selected the relevant studies and extracted the data, and also risk of bias was estimated by other 2 independent reviewers. The reference standard was determined by TEE detection, which is a gold standard test for the diagnosis of left atrial SEC/LAT. The pooled sample size was large enough to estimate the mean DD difference between two groups, and verify the association and the diagnostic accuracy of DD on the presence of LAT. Subgroup analyses and meta-regression were also performed to explore the source of heterogeneity. In addition, no significant publication bias was found.

There are a few limitations inherent to this meta-analysis. First, heterogeneity was high in all pooled analyses even after associated factors were adjusted. Our meta-regression analysis indicated that sample size was a source of heterogeneity (coefficient = -0.004, p = 0.033) when pooling SMDs of16 included studies. Some of the included studies were small in size (≤100 cases, 8/16) and 6 studies enrolled patients non-consecutively (6/16). Second, more than 5 kinds of DD assays and various cutoff values (range from 0.125 to 4.0 ug/ml) were used across the included studies. Although different DD assays displayed very similar tendency \[[@pone.0172272.ref045]\], our meta-regression indicated that cutoff values and mean age contributed to a part of the sources of heterogeneity. Moreover, a large prospective diagnostic management outcome study has demonstrated that age-adjusted DD cutoff was superior to a fixed one to rule out thromboembolism \[[@pone.0172272.ref046]\]. However, without individual patient data from each study, it was difficult to distinguish and calibrate the optimal cutoff values of DD. Third, due to the study design of the original included studies, the causal relationship could not be concluded between DD and SEC/LAT. Another potential bias is the absence of clear policy regarding antithrombotic treatment regimens and the lack of evaluation of such treatment on DD cutoff values. In addition, some key clinical endpoints, such as ischemic stroke and systemic embolism, which were thought to be the major risk of SEC/LAT, were not included in our meta-analysis. Future studies should encompass well-designed prospective cohort studies with balanced age, standardized DD assays and an uniform cutoff value, and be required to clarify the following two questions: ① if DD is temporally associated with the development of LAT, and ②if DD-guided anticoagulant therapy has a favorable impact on thrombosis and thromboembolisms.

Conclusions {#sec018}
===========

Notwithstanding the limitations of observational studies and indirect data, this systematic review demonstrated that DD elevated among patients with SEC/LAT, particularly in those with LAT. DD levels had moderate sensitivity and specificity for diagnosing LAT in conditions leading to left atrial stasis, such as AF and mitral stenosis. These findings suggest that DD may benefit the risk stratification of patients with atrial fibrillation, providing further evidence for anticoagulation therapy among patients susceptible to left atrial SEC/LAT.
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